Revelation Biosciences (REVB) Q3 2026 earnings review
Revelation's loss widens, and its cash lasts under a year
Revelation Biosciences put more money into its kidney drug trial, while its overhead climbed faster. The San Diego company is developing Gemini, a drug for sudden kidney failure in hospital patients. Its quarterly loss widened 74% from a year ago. It ended September with $9.1 million and warned that this cash will not last a year.
| Net loss | $3.3M $1.9M a year ago |
|---|---|
| Cash at the end of September | $9.1M $11.5M at the end of June |
| Spending on the kidney injury programme | $816K $286K a year ago |
| Cash outlook | Unchanged cash lasts into Q1 2027 |
⚖️ Verdict: 🔴 Bearish
The story got worse, because overhead took more new money than research while Revelation still needs fresh funding. Spending on the kidney injury programme almost tripled. But rights to buy shares, issued in past deals, now cover nearly four times the shares outstanding, so the next raise will shrink existing owners' stake.
The question now is whether Revelation can open its trial and raise money before cash runs out in early 2027. It could sell new shares, or let holders of those rights buy at $3.29 each, and both routes add many shares. The fourth-quarter report and any enrollment news will settle it.
🐂 Bull Case
Kidney Injury Work Now Gets Most Research Money
Revelation is developing Gemini, a drug meant to calm the immune overreaction behind acute kidney injury, a sudden loss of kidney function. The biotech sees the shortest path to approval in this use.
In the third quarter it spent $816,000 on the kidney injury programme, almost three times the year-ago sum. Spending on chronic kidney disease, its second programme, went to zero from $286,000.
This matters because Revelation cannot afford several trials at once, so focusing its research money gives the kidney injury study the best chance to start. But the shift also ties the company to one trial.
What to watch: fourth-quarter research spending, due in the annual report early next year. A clear step up would show the trial has moved from planning to treating patients.
One Trial Could Support Approval of Gemini
US regulators agreed to a single combined study for Gemini, Revelation's immune-balancing drug, in acute kidney injury. The company's presentation lists the "Adaptive design and study endpoints agreed to with FDA" and says the trial "will enroll approximately 300 patients total".
The trial first tests several doses against a placebo, then carries the safest one into the final stage. Early patients still count, because "Data from Phase 2 counts towards data necessary for final analysis".
Revelation spent $607,000 this year making trial drug. One combined trial saves the time and money of running two studies, but it still has to reduce deaths or dialysis among patients.
What to watch: the study size after the first stage, because "Sample size will be evaluated and adjusted if necessary". A larger study would need more cash than Revelation holds today.
🐻 Bear Case
Cash Will Not Last Through the Kidney Trial
Revelation has no sales, so it pays for research with money from investors. Its quarterly filing warns of "substantial doubt about its ability to continue as a going concern", because the biotech does not expect its cash to last a year.
Cash dropped by $2.4 million in the third quarter, and Revelation raised no new money. Its March presentation pointed to "Cash into Q1 2027" and promised enough to "open enrollment" in its acute kidney injury trial, not to finish it.
- Cash at the end of September: $9.1 million, against $11.5 million in June
- Cash used in operations, first nine months: $8.1 million, up from $6.3 million a year earlier
This matters because the trial is the expensive part, and its costs have not arrived yet. Revelation expects research spending to "increase substantially for the foreseeable future", so the third quarter's pace understates what comes next.
What to watch: the cash balance and the date it lasts until, both due in the annual report early next year. A raise before then would push that date out, but each deal so far has also added many new shares.
Share Count Tripled, and Warrants Add Far More
Revelation pays for research by selling shares and warrants, which give investors the right to buy new shares later at a set price. Each new deal has "triggered the down-round feature" in older warrants, which cuts their price and can enlarge the shares they cover.
Shares outstanding reached 683,442 at the end of September, three times the December count. Most of that came from a January deal in which two investors exercised warrants for $6.7 million.
In October Revelation carried out another reverse split, which merges existing shares into fewer ones. The split cut the warrant price to $3.29 and lifted the shares they cover to about 2.6 million. By our math, that is 3.9 times the shares outstanding.
This matters because the trial needs more money, and each raise so far has pushed older warrant prices lower. If holders exercise, Revelation gains cash, but owners of today's shares end up with a much smaller part of the company.
What to watch: the terms of the next financing, which Revelation plans to seek through share sales or debt. Another reset of warrant prices would show the pattern continues.
Overhead Costs Grew Faster Than Research
Revelation's filing says its operating costs "consist primarily of research and development expenditures". In the third quarter, general and administrative costs, the overhead for executives, legal work and accounting, again exceeded research.
Overhead rose 83% from a year ago, while research spending climbed 64%. Pay in shares drove much of the gap, reaching $437,000 in overhead against almost nothing a year earlier.
This matters because each dollar spent on offices and share awards is a dollar the kidney injury trial cannot use. Overhead topped research in four of the last five quarters, so the filing's description does not match the spending.
What to watch: overhead against research in the fourth quarter. Once the trial treats patients, research should pull clearly ahead; if overhead still leads, cash will run out sooner.
Filing Gives No Update on Trial Start
Revelation has aimed to start enrolling patients by the end of 2026 in its trial for acute kidney injury, a sudden loss of kidney function. Its second-quarter report kept that goal.
The third-quarter filing does not mention enrollment. Research spending fell 21% from the second quarter. Spending on making trial drug dropped to $62,000, after about $545,000 in the first half.
That pattern fits a trial that has not yet started treating patients, because sites and patients would push costs up, not down. But a pause in drug manufacturing can also mean Revelation already holds enough supply.
What to watch: news of the first patient enrolled, due by year-end under the company's own target. A delay would push the trial's costs into the months when cash is shortest.
👓 Other Themes
Revelation Adopts a Shareholder Rights Plan
Revelation adopted a shareholder rights plan in July. If an investor takes 10% or more without board approval, other holders can buy new preferred shares, making that stake costly. Revelation said it designed the plan to "protect stockholder value and deter coercive or unfair takeover tactics". The plan expires in July 2027 unless shareholders approve it.
💲 Other KPIs
Bills owed to suppliers rose 85% since December, to $1.07 million. They now equal 31.5% of a quarter's operating costs, the highest share this year. Unpaid payroll costs moved the other way, down by a third since December.
The loss per share narrowed to $5.92 from $49.51 a year ago. That reflects an average share count almost six times larger, not a smaller loss. The year-ago figure also included $2.8 million of deemed dividends, an accounting charge for cutting warrant prices.
Shareholders' equity, assets minus liabilities, fell to $7.2 million from $10.1 million in June. No new money came in during the quarter, so the net loss came straight out of equity. Pay in shares added back $0.5 million.
🔮 Guidance
Unchanged. Revelation's March presentation says cash lasts into the first quarter of 2027, and the quarterly filing warns it will not last a year. By our math, that allows about $4.6 million of spending a quarter from here, almost double the third quarter's pace. Planned trial costs explain the gap. The date has held for three quarters, after a move from the third quarter of 2026.
Unchanged, but not repeated. The plan still calls for the combined Phase 2/3 study, which tests doses and then moves to the approval stage, to enroll patients this year. The second-quarter report set that goal, and the March presentation said the study would begin this year. The quarterly filing adds no date, so the fourth quarter decides it.
New. Revelation plans for research spending to "increase substantially for the foreseeable future" as the kidney injury trial grows. Third-quarter research spending came to $1.5 million, below the second quarter's $1.9 million, so the rise has not started. The spending allowed by the cash date leaves room for it.
❓ Key Questions
Has the kidney injury trial enrolled its first patient?
Revelation aimed to start enrollment by the end of 2026, but its quarterly filing gives no update. Research spending fell from the second quarter, so readers need the start date and the number of sites open.
How much will the trial cost each quarter?
The cash date in early 2027 allows roughly twice the third quarter's spending. Revelation has not said what the full study of about 300 patients costs, or how much of it current cash covers.
How will Revelation pay for the trial after early 2027?
The biotech warns cash will not last a year. Warrants could bring in money at $3.29 a share, but they would multiply the share count. Investors need the funding plan.
Why did overhead rise faster than research spending?
Overhead grew 83% from a year ago, led by pay in shares and professional fees. The filing says research is the main use of cash, yet overhead topped research in four of five quarters.
What prompted the shareholder rights plan in July?
The board adopted the plan to deter takeover tactics but did not say whether any investor had approached a 10% stake.